Literature DB >> 16414997

Paramyxovirus receptor-binding molecules: engagement of one site on the hemagglutinin-neuraminidase protein modulates activity at the second site.

Matteo Porotto1, Micaela Fornabaio, Olga Greengard, Matthew T Murrell, Glen E Kellogg, Anne Moscona.   

Abstract

The hemagglutinin-neuraminidase (HN) protein of paramyxoviruses carries out three different activities: receptor binding, receptor cleaving (neuraminidase), and triggering of the fusion protein. These three discrete properties each affect the ability of HN to promote viral fusion and entry. For human parainfluenza type 3, one bifunctional site on HN can carry out both binding and neuraminidase, and the receptor mimic, zanamivir, impairs viral entry by blocking receptor binding. We report here that for Newcastle disease virus, the HN receptor avidity is increased by zanamivir, due to activation of a second site that has higher receptor avidity. Only certain receptor mimics effectively activate the second site (site II) via occupation of site I; yet without activation of this second site, binding is mediated entirely by site I. Computational modeling designed to complement the experimental approaches suggests that the potential for small molecule receptor mimics to activate site II, upon binding to site I, directly correlates with their predicted strengths of interaction with site I. Taken together, the experimental and computational data show that the molecules with the strongest interactions with site I-zanamivir and BCX 2798-lead to the activation of site II. The finding that site II, once activated, shows higher avidity for receptor than site I, suggests paradigms for further elucidating the regulation of HN's multiple functions in the viral life cycle.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16414997      PMCID: PMC1346948          DOI: 10.1128/JVI.80.3.1204-1213.2006

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  28 in total

1.  Probing the sialic acid binding site of the hemagglutinin-neuraminidase of Newcastle disease virus: identification of key amino acids involved in cell binding, catalysis, and fusion.

Authors:  Helen Connaris; Toru Takimoto; Rupert Russell; Susan Crennell; Ibrahim Moustafa; Allen Portner; Garry Taylor
Journal:  J Virol       Date:  2002-02       Impact factor: 5.103

2.  Simple, intuitive calculations of free energy of binding for protein-ligand complexes. 1. Models without explicit constrained water.

Authors:  Pietro Cozzini; Micaela Fornabaio; Anna Marabotti; Donald J Abraham; Glen E Kellogg; Andrea Mozzarelli
Journal:  J Med Chem       Date:  2002-06-06       Impact factor: 7.446

3.  Computationally accessible method for estimating free energy changes resulting from site-specific mutations of biomolecules: systematic model building and structural/hydropathic analysis of deoxy and oxy hemoglobins.

Authors:  J C Burnett; P Botti; D J Abraham; G E Kellogg
Journal:  Proteins       Date:  2001-02-15

4.  Mutations in human parainfluenza virus type 3 hemagglutinin-neuraminidase causing increased receptor binding activity and resistance to the transition state sialic acid analog 4-GU-DANA (Zanamivir).

Authors:  Matthew Murrell; Matteo Porotto; Thomas Weber; Olga Greengard; Anne Moscona
Journal:  J Virol       Date:  2003-01       Impact factor: 5.103

5.  The anti-influenza virus agent 4-GU-DANA (zanamivir) inhibits cell fusion mediated by human parainfluenza virus and influenza virus HA.

Authors:  O Greengard; N Poltoratskaia; E Leikina; J Zimmerberg; A Moscona
Journal:  J Virol       Date:  2000-12       Impact factor: 5.103

6.  Triggering of human parainfluenza virus 3 fusion protein (F) by the hemagglutinin-neuraminidase (HN) protein: an HN mutation diminishes the rate of F activation and fusion.

Authors:  Matteo Porotto; Matthew Murrell; Olga Greengard; Anne Moscona
Journal:  J Virol       Date:  2003-03       Impact factor: 5.103

7.  Structural features of paramyxovirus F protein required for fusion initiation.

Authors:  Richard K Plemper; Ami S Lakdawala; Kim M Gernert; James P Snyder; Richard W Compans
Journal:  Biochemistry       Date:  2003-06-10       Impact factor: 3.162

8.  Conformational changes of Newcastle disease virus envelope glycoproteins triggered by gangliosides.

Authors:  Laura Ferreira; Enrique Villar; Isabel Muñoz-Barroso
Journal:  Eur J Biochem       Date:  2004-02

9.  Fusion deficiency induced by mutations at the dimer interface in the Newcastle disease virus hemagglutinin-neuraminidase is due to a temperature-dependent defect in receptor binding.

Authors:  Elizabeth A Corey; Anne M Mirza; Elizabeth Levandowsky; Ronald M Iorio
Journal:  J Virol       Date:  2003-06       Impact factor: 5.103

10.  Simple, intuitive calculations of free energy of binding for protein-ligand complexes. 2. Computational titration and pH effects in molecular models of neuraminidase-inhibitor complexes.

Authors:  Micaela Fornabaio; Pietro Cozzini; Andrea Mozzarelli; Donald J Abraham; Glen E Kellogg
Journal:  J Med Chem       Date:  2003-10-09       Impact factor: 7.446

View more
  39 in total

1.  A recombinant sialidase fusion protein effectively inhibits human parainfluenza viral infection in vitro and in vivo.

Authors:  Anne Moscona; Matteo Porotto; Samantha Palmer; Caroline Tai; Lori Aschenbrenner; Gallen Triana-Baltzer; Qi-Xiang Li; David Wurtman; Stefan Niewiesk; Fang Fang
Journal:  J Infect Dis       Date:  2010-07-15       Impact factor: 5.226

Review 2.  Modes of paramyxovirus fusion: a Henipavirus perspective.

Authors:  Benhur Lee; Zeynep Akyol Ataman
Journal:  Trends Microbiol       Date:  2011-04-20       Impact factor: 17.079

3.  Mutation at residue 523 creates a second receptor binding site on human parainfluenza virus type 1 hemagglutinin-neuraminidase protein.

Authors:  Tatiana Bousse; Toru Takimoto
Journal:  J Virol       Date:  2006-09       Impact factor: 5.103

4.  A second receptor binding site on human parainfluenza virus type 3 hemagglutinin-neuraminidase contributes to activation of the fusion mechanism.

Authors:  Matteo Porotto; Micaela Fornabaio; Glen E Kellogg; Anne Moscona
Journal:  J Virol       Date:  2007-01-17       Impact factor: 5.103

5.  Theoretical calculations of the catalytic triad in short-chain alcohol dehydrogenases/reductases.

Authors:  Osman A B S M Gani; Olayiwola A Adekoya; Laura Giurato; Francesca Spyrakis; Pietro Cozzini; Salvatore Guccione; Jan-Olof Winberg; Ingebrigt Sylte
Journal:  Biophys J       Date:  2007-11-02       Impact factor: 4.033

6.  Role of the two sialic acid binding sites on the newcastle disease virus HN protein in triggering the interaction with the F protein required for the promotion of fusion.

Authors:  Paul J Mahon; Anne M Mirza; Ronald M Iorio
Journal:  J Virol       Date:  2011-08-31       Impact factor: 5.103

7.  Premature activation of the paramyxovirus fusion protein before target cell attachment with corruption of the viral fusion machinery.

Authors:  Shohreh F Farzan; Laura M Palermo; Christine C Yokoyama; Gianmarco Orefice; Micaela Fornabaio; Aurijit Sarkar; Glen E Kellogg; Olga Greengard; Matteo Porotto; Anne Moscona
Journal:  J Biol Chem       Date:  2011-07-28       Impact factor: 5.157

8.  Fusion activation by a headless parainfluenza virus 5 hemagglutinin-neuraminidase stalk suggests a modular mechanism for triggering.

Authors:  Sayantan Bose; Aarohi Zokarkar; Brett D Welch; George P Leser; Theodore S Jardetzky; Robert A Lamb
Journal:  Proc Natl Acad Sci U S A       Date:  2012-09-04       Impact factor: 11.205

9.  Regulation of paramyxovirus fusion activation: the hemagglutinin-neuraminidase protein stabilizes the fusion protein in a pretriggered state.

Authors:  Matteo Porotto; Zuhair W Salah; Long Gui; Ilaria DeVito; Eric M Jurgens; Hong Lu; Christine C Yokoyama; Laura M Palermo; Kelly K Lee; Anne Moscona
Journal:  J Virol       Date:  2012-09-19       Impact factor: 5.103

10.  Inhibition of Nipah virus infection in vivo: targeting an early stage of paramyxovirus fusion activation during viral entry.

Authors:  Matteo Porotto; Barry Rockx; Christine C Yokoyama; Aparna Talekar; Ilaria Devito; Laura M Palermo; Jie Liu; Riccardo Cortese; Min Lu; Heinz Feldmann; Antonello Pessi; Anne Moscona
Journal:  PLoS Pathog       Date:  2010-10-28       Impact factor: 6.823

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.